title: Phase II study with a new alkylating agent (PTT-119) in lymphoid malignancies.
authors.forename: S
authors.initials: S
authors.lastname: Tura
authors.forename: P
authors.initials: P
authors.lastname: Mazza
authors.forename: F
authors.initials: F
authors.lastname: Gherlinzoni
authors.forename: P L
authors.initials: PL
authors.lastname: Zinzani
authors.forename: G
authors.initials: G
authors.lastname: Poletti
authors.forename: G
authors.initials: G
authors.lastname: Visani
authors.forename: R M
authors.initials: RM
authors.lastname: Lemoli
authors.forename: G
authors.initials: G
authors.lastname: Bandini
authors.forename: M
authors.initials: M
authors.lastname: Cavo
authors.forename: P
authors.initials: P
authors.lastname: Galieni
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; C038259:ambamustine